Hydroxyurea, the only drug frequently used for SCA therapy, is a cytostatic agent, although it appears to exert nitric oxide/soluble guanylyl cyclase (sGC) modulating activity. This evidence concerns the gene SGCB and autosomal dominant cerebellar ataxia.